Kimberly S. Clarke

Kimberly S. Clarke is a clinical scientist and translational therapeutics executive whose career spans oncology, transplant immunology, radiotherapeutics, cell and gene therapy, and global clinical development. Her scientific foundation traces directly through Dr. Fritz H. Bach, pioneer of the Mixed Leukocyte Culture assay, whose work shaped modern transplant immunology. Clarke trained within the Minnesota transplant ecosystem, gaining deep expertise in HLA biology, mixed-lymphocyte culture, alloreactivity, and T-cell discrimination—principles that continue to inform today’s engineered cell and immune-modulating therapies. She spent nearly two decades delivering high-precision radiation therapy, total-body irradiation, and bone-marrow transplant workflows, integrating radiobiology, physics, dosimetry, imaging, and safety-critical operational execution across a multi-center network. This clinical foundation shaped her translational approach: therapies must be mechanistically sound, operationally feasible, and aligned with real-world patient needs. Her translational work includes advancing HO-1–based cytoprotective therapeutics, biliverdin platforms, and device-enabled inhaled CO delivery from concept through large-animal studies and first-in-human trials in Europe. She later led global early-phase oncology, rare-disease, and CGT programs across biopharma, including pivotal CAR T-Cell trials contributing to the approvals of Yescarta and Tecartus. At IQVIA, she conceived and architected the Radiotherapeutics Center of Excellence, integrating imaging, dosimetry, regulatory strategy, and nuclear-material logistics to support next-generation radiotherapeutic platforms. Today, Clarke guides enterprise-level oncology strategy across multimodal therapeutic platforms. Her work operates within six mechanistic pillars—Radiation, Conditioning, Immune Biology, Regulatory, Dosimetry/Imaging/Physics/Treatment Planning, and Safety-Critical Operational Execution—forming a single, coherent system that underpins her scientific and operational judgment. Across radiation, transplant, conditioning, and advanced therapeutics, her work carries the same non-negotiable reality: you have one chance to get it right.